ADPT: Adaptive Biotech Company Value to Net Income
Adaptive Biotechnologies revenues are based on the sale of diagnostic systems and partnerships with pharmaceutical behemoths. The company's price-to-earnings ratio serves as an indicator of market confidence, where the value -70.10 describes the current valuation level of the asset. Growth is driven by the scaling of clonoSEQ technology through multi-billion dollar contracts, while genome analysis relies on flexible integration with external cloud services.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ADPT_-_Adaptive-Biotechnologies_-_PE-Multiple "ADPT: Adaptive Biotechnologies Business Payback Period 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Adaptive Biotechnologies Corp (ADPT)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Adaptive Biotechnologies|ADPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Adaptive Biotechnologies Inc.|ADPT - Company Debts|Debt to Book Value Ratio Adaptive Biotechnologies Corporation|ADPT - Company Long-Term Debts|Short-Term Debt Adaptive Biotechnologies|Quick Ratio adaptivebiotech.com
- earnings and market multiples details:
ADPT - Net Profit|Net Profit Forecast Adaptive Biotechnologies|ADPT - P/E Multiple|Forward P/E Multiple Adaptive Biotech|ADPT - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Adaptive Biotechnologies Corporation|ADPT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Adaptive Biotechnologies|ADPT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months adaptivebiotech.com|ADPT - Net earnings per share growth this year|Net earnings per share growth forecast for next year Adaptive Biotechnologies
Comprehensive company analysis:adaptivebiotech.com ADPT
The P/E ratio reflects business value through the relationship between market price and annual earnings, allowing for an assessment of cash flow generation efficiency. Given Adaptive Biotechnologies (ADPT) dependence on FDA verdicts and the slow expansion of its client base, the company's consolidated P/E helps distinguish temporary asset undervaluation from a systemic model crisis, eliminating the risk of investing in a "value trap."
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Celldex Therapeutics Inc|Price to Earnings Ratio AUPH|P/E Multiple BioCryst Corp|Price to Earnings Ratio Vera Therapeutics, Inc. (VERA)|dianthustx.com - Price to Earnings Multiple|P/E Multiple PHVS (Pharvaris)|AbCellera Corp (ABCL) - Market Cap to Earnings|Tourmaline Corp - P/E Multiple|PGEN - P/E Multiple|PHAR: P/E Multiple|Price to Earnings Multiple NKTR|UPB (Upstream Bio) - P/E Multiple|P/E Multiple Zenas Bio|Price to Earnings Ratio Immunome Corp (IMNM)|GOSS: Market Cap to Net Income|KalVista Pharmaceuticals - Price to Earnings Ratio|Market Price to Net Income Ratio SEPN (septerna.com)|Pieris Pharmaceuticals, Inc. - P/E Multiple|Business Payback Period Savara Inc SVRA|RIGL (Rigel Pharmaceuticals Inc) - Price to Earnings Ratio|ANAB (AnaptysBio Inc.) - Price to Earnings Ratio|ATXS (Astria Therapeutics) - P/E Multiple|Market Cap to Earnings engene.com ENGN|Price to Earnings Ratio RAPT (RAPT Therapeutics)|JBIO (aerovatetx.com) - Company Value to Net Income|P/E Multiple ACRS (Aclaris)|Kyverna Therapeutics, Inc - Price to Earnings Ratio|Tiziana Life Sciences - P/E Multiple|Business Payback Period cabalettabio.com CABA|Ventyx Biosciences, Inc. (VTYX) - Price to Earnings Ratio|Market Cap to Earnings Theratechnologies, Inc. (THTX)|Price to Earnings Ratio AVTX|ELDN (Eledon Pharmaceuticals, Inc) - Market Price to Net Income Ratio|P/E Multiple AGEN|CLYM - Market Cap to Earnings|P/E Multiple ZURA (Zura Bio)|ATYR - Price to Earnings Ratio|Adagene Corp - P/E Multiple|Company Value to Net Income IMA (ImageneBio Inc)|shattucklabs.com (STTK) - Price to Earnings Ratio|Price to Earnings Multiple EQ|Price to Earnings Ratio Connect Biopharma Holdings|Market Cap to Earnings Immunic Inc IMUX|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|Price to Earnings Ratio IFRX (inflarx.de)|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Adicet Bio Inc. (ACET) - Market Cap to Earnings|Celularity Corp - P/E Multiple|Market Cap to Net Income Ratio INmune Bio Inc (INMB)|BRNS: P/E Multiple|KZR - Business Payback Period|SABS (SAB Biotherapeutics) - P/E Multiple|Market Cap to Earnings akaritx.com AKTX|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|Business Payback Period q32bio.com|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|iBio, Inc. - P/E Multiple|CARM (Carisma Therapeutics) - Price to Earnings Multiple|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Market Cap to Net Income BOLT (Bolt Biotherapeutics, Inc.)|Price to Earnings Ratio HCWB|APVO (Aptevo) - Market Price to Net Income Ratio|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|ADTX: Market Cap to Net Income|P/E Multiple GRI (GRI Bio)|Company Value to Net Income XRTX|ReShape Lifesciences - P/E Multiple|REVB - P/E Multiple|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|P/E Multiple ALLK|P/E Multiple hookipapharma.com (HOOK)|IGM Biosciences - Price to Earnings Ratio|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|Business Payback Period TC BioPharm (Holdings) Plc TCBP|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
